Posted by ABMN Staff on Apr 27th, 2024
Biogen (NASDAQ:BIIB – Get Free Report) had its target price lowered by equities research analysts at HC Wainwright from $325.00 to $300.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The...
More of this article »